<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01073800</url>
  </required_header>
  <id_info>
    <org_study_id>VASTVALUS</org_study_id>
    <nct_id>NCT01073800</nct_id>
  </id_info>
  <brief_title>Using AtorVASTatin to Prevent VAscular Inflammatory OccLUSion in the Critically Ill</brief_title>
  <acronym>VASTVALUS</acronym>
  <official_title>Using AtorVASTatin to Prevent VAscular Inflammatory OccLUSion in the Critically Ill</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients are admitted to the critical care unit of the hospital because of medical conditions&#xD;
      that have a high likelihood of causing severe problems with blood flow, breathing, or brain&#xD;
      function. These conditions also have a high likelihood of causing death. Approximately 10 to&#xD;
      15% of all critically ill patients die in hospital. A large amount of scientific evidence&#xD;
      suggests that a substantial proportion of these deaths is due to a combination of blot&#xD;
      clotting and inflammation in the blood vessels.&#xD;
&#xD;
      Statins are drugs that interfere with cholesterol and fat metabolism. Cholesterol and fat in&#xD;
      the blood are associated with blood clotting and inflammation in the blood vessels. Statins&#xD;
      are known to be very beneficial in improving the survival after heart attacks, and in&#xD;
      preventing heart attacks.&#xD;
&#xD;
      The question that VASTVALUS asks is: do statins improve survival among all critically ill&#xD;
      patients? In VASTVALUS, we will concentrate on patients that do not currently require a&#xD;
      statin because of their medical condition e.g. after a heart attack, but we are concerned&#xD;
      with the rest of the critically ill. In VASTVALUS, participating patients will receive either&#xD;
      atorvastatin 80 mg daily or a placebo. Atorvastatin is a statin with a well-established&#xD;
      record of safety and effectiveness. A placebo has no known medical activity. We will follow&#xD;
      all patients in VASTVALUS to determine whether atorvastatin has any effect on the occurrence&#xD;
      of death, stroke, heart attack, or kidney failure among the critically ill. Results from&#xD;
      VASTVALUS will be shared with the medical community after the study is completed. As with all&#xD;
      clinical trials, patients in VASTVALUS participate of their own choice, and can change their&#xD;
      mind at any time.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>vascular occlusive events</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>liver enzyme elevation</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rhabdomyolysis</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myalgias</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Stroke</condition>
  <condition>Renal Failure</condition>
  <arm_group>
    <arm_group_label>atorvastatin 80 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>active treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin 80 mg per os daily</intervention_name>
    <description>atorvastatin 80 mg per os daily</description>
    <arm_group_label>atorvastatin 80 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Men or women &gt;18 years of age&#xD;
&#xD;
          -  2. Admitted to a critical care unit and requiring at least a 48 hour critical care&#xD;
             unit stay for medical reasons. Medical reasons include:&#xD;
&#xD;
               -  conditions of cardiovascular,&#xD;
&#xD;
               -  respiratory, or&#xD;
&#xD;
               -  neurologic impairment that require supportive care and observation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Hepatic failure (Childs-Pugh class C)&#xD;
&#xD;
          -  2. Rhabdomyolysis&#xD;
&#xD;
          -  3. Allergy or hypersensitivity to this drug or any of its components&#xD;
&#xD;
          -  4. Previous intolerance&#xD;
&#xD;
          -  5. Enrolment in another interventional trial&#xD;
&#xD;
          -  6. Contraindication to gastric and/or small bowel drug administration&#xD;
&#xD;
          -  7. MI as major diagnosis at admission (statin indicated)&#xD;
&#xD;
          -  8. Coronary artery intervention within previous 3 days&#xD;
&#xD;
          -  9. Currently receiving a statin or indicated (MI, dyslipidemia)&#xD;
&#xD;
          -  10. Pregnancy&#xD;
&#xD;
          -  11. personal or family history of hereditary muscular disorders&#xD;
&#xD;
          -  12. previous history of muscle toxicity with another HMG-CoA reductase Inhibitor&#xD;
&#xD;
          -  13. concomitant use of a fibrate or niacin&#xD;
&#xD;
          -  14. hypothyroidism&#xD;
&#xD;
          -  15. alcohol abuse&#xD;
&#xD;
          -  16. excessive physical exercise&#xD;
&#xD;
          -  17. renal impairment&#xD;
&#xD;
          -  18. diabetes with hepatic fatty change&#xD;
&#xD;
          -  19. surgery and trauma&#xD;
&#xD;
          -  20. frailty&#xD;
&#xD;
          -  21. situations where an increased plasma level of active ingredient may occur&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>July 20, 2009</study_first_submitted>
  <study_first_submitted_qc>February 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2010</study_first_posted>
  <last_update_submitted>December 15, 2011</last_update_submitted>
  <last_update_submitted_qc>December 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atorvastatin</keyword>
  <keyword>vascular occlusion</keyword>
  <keyword>myocardial infarction</keyword>
  <keyword>stroke</keyword>
  <keyword>renal failure</keyword>
  <keyword>critically ill</keyword>
  <keyword>Vascular occlusive events among the critically ill</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

